Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 48

1.

Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer.

Chrischilles EA, Pendergast JF, Kahn KL, Wallace RB, Moga DC, Harrington DP, Kiefe CI, Weeks JC, West DW, Zafar SY, Fletcher RH.

J Clin Oncol. 2010 Feb 1;28(4):620-7. doi: 10.1200/JCO.2009.23.8485. Epub 2009 Dec 28. Erratum in: J Clin Oncol. 2010 May 1;28(13):2314.

PMID:
20038726
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Use of adjuvant chemotherapy in non-small cell lung cancer in routine practice.

Massard C, Tran Ba Loc P, Haddad V, Pignon JP, Girard P, Monnet I, Trédaniel J, Besse B, Soria JC.

J Thorac Oncol. 2009 Dec;4(12):1504-10. doi: 10.1097/JTO.0b013e3181bbf1c9.

PMID:
19745763
[PubMed - indexed for MEDLINE]
3.

Effects of CERA (continuous erythropoietin receptor activator) in patients with advanced non-small-cell lung cancer (NSCLC) receiving chemotherapy: results of a phase II study.

Gascon P, Pirker R, Del Mastro L, Durrwell L.

Ann Oncol. 2010 Oct;21(10):2029-39. doi: 10.1093/annonc/mdq073. Epub 2010 Mar 24.

PMID:
20335369
[PubMed - indexed for MEDLINE]
Free Article
4.

Treatment of advanced non-small-cell lung cancer with Chinese herbal medicine by stages combined with chemotherapy.

Xu ZY, Jin CJ, Zhou CC, Wang ZQ, Zhou WD, Deng HB, Zhang M, Su W, Cai XY.

J Cancer Res Clin Oncol. 2011 Jul;137(7):1117-22. doi: 10.1007/s00432-011-0975-3. Epub 2011 Feb 5.

PMID:
21298288
[PubMed - indexed for MEDLINE]
5.

Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.

Smit EF, Burgers SA, Biesma B, Smit HJ, Eppinga P, Dingemans AM, Joerger M, Schellens JH, Vincent A, van Zandwijk N, Groen HJ.

J Clin Oncol. 2009 Apr 20;27(12):2038-45. doi: 10.1200/JCO.2008.19.1650. Epub 2009 Mar 23.

PMID:
19307503
[PubMed - indexed for MEDLINE]
Free Article
6.

Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.

Scagliotti G, Novello S, von Pawel J, Reck M, Pereira JR, Thomas M, Abrão Miziara JE, Balint B, De Marinis F, Keller A, Arén O, Csollak M, Albert I, Barrios CH, Grossi F, Krzakowski M, Cupit L, Cihon F, Dimatteo S, Hanna N.

J Clin Oncol. 2010 Apr 10;28(11):1835-42. doi: 10.1200/JCO.2009.26.1321. Epub 2010 Mar 8.

PMID:
20212250
[PubMed - indexed for MEDLINE]
Free Article
7.

[Evaluation of combined chemotherapy with vinorelbine, ifosfamide and cisplatin in the treatment of metastatic non-small cell bronchial carcinoma].

Boutemy M, Mispelaere D, Krzisch C, Jounieaux V.

Rev Mal Respir. 2005 Jun;22(3):413-9. French.

PMID:
16227927
[PubMed - indexed for MEDLINE]
8.

Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Radiation Therapy Oncology Group. Eastern Cooperative Oncology Group.

Komaki R, Scott CB, Sause WT, Johnson DH, Taylor SG 4th, Lee JS, Emami B, Byhardt RW, Curran WJ Jr, Dar AR, Cox JD.

Int J Radiat Oncol Biol Phys. 1997 Oct 1;39(3):537-44.

PMID:
9336129
[PubMed - indexed for MEDLINE]
9.

Randomized phase II study of paclitaxel and carboplatin or vinorelbine in advanced non-small cell lung cancer.

Jahnke K, Keilholz U, Lüftner D, Thiel E, Schmittel A.

Anticancer Res. 2011 Jan;31(1):317-23.

PMID:
21273617
[PubMed - indexed for MEDLINE]
10.

Cisplatin combination chemotherapy induces oxidative stress in advance non small cell lung cancer patients.

Srivastava AN, Gupta A, Srivastava S, Natu SM, Mittal B, Negi MP, Prasad R.

Asian Pac J Cancer Prev. 2010;11(2):465-71.

PMID:
20843135
[PubMed - indexed for MEDLINE]
Free Article
11.

The influence of sex on efficacy, adverse events, quality of life, and delivery of treatment in National Cancer Institute of Canada Clinical Trials Group non-small cell lung cancer chemotherapy trials.

Wheatley-Price P, Le Maître A, Ding K, Leighl N, Hirsh V, Seymour L, Bezjak A, Shepherd FA; NCIC Clinical Trials Group.

J Thorac Oncol. 2010 May;5(5):640-8. doi: 10.1097/JTO.0b013e3181d40a1b.

PMID:
20354457
[PubMed - indexed for MEDLINE]
12.

Survival rates and tolerability of platinum-based chemotherapy regimens for elderly patients with non-small-cell lung cancer (NSCLC).

Costa GJ, Fernandes AL, Pereira JR, Curtis JR, Santoro IL.

Lung Cancer. 2006 Aug;53(2):171-6. Epub 2006 Jun 6.

PMID:
16757059
[PubMed - indexed for MEDLINE]
13.

Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC).

Glorieux P, Ortmanns P, Marien S, Degives R, Degraeve D, Potvin M, Grauwels D, Schallier D.

Anticancer Res. 2001 Mar-Apr;21(2B):1487-94.

PMID:
11396237
[PubMed - indexed for MEDLINE]
14.

Circulating endothelial cells in non-small cell lung cancer patients treated with carboplatin and paclitaxel.

Kawaishi M, Fujiwara Y, Fukui T, Kato T, Yamada K, Ohe Y, Kunitoh H, Sekine I, Yamamoto N, Nokihara H, Watabe T, Shimoda Y, Arao T, Nishio K, Tamura T, Koizumi F.

J Thorac Oncol. 2009 Feb;4(2):208-13. doi: 10.1097/JTO.0b013e318193030d.

PMID:
19179898
[PubMed - indexed for MEDLINE]
15.

Phase II trial of amrubicin for second-line treatment of advanced non-small cell lung cancer: results of the West Japan Thoracic Oncology Group trial (WJTOG0401).

Kaneda H, Okamoto I, Hayashi H, Yoshioka H, Miyazaki M, Kudoh S, Kimura T, Sugiura T, Sawa T, Takeda K, Iwamoto Y, Satouchi M, Akita K, Saito H, Goto I, Shibata K, Fukuoka M, Nakagawa K; West Japan Thoracic Oncology Group.

J Thorac Oncol. 2010 Jan;5(1):105-9. doi: 10.1097/JTO.0b013e3181c07c6c.

PMID:
19884859
[PubMed - indexed for MEDLINE]
16.

Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.

Chiappori AA, Haura E, Rodriguez FA, Boulware D, Kapoor R, Neuger AM, Lush R, Padilla B, Burton M, Williams C, Simon G, Antonia S, Sullivan DM, Bepler G.

Clin Cancer Res. 2008 Mar 1;14(5):1464-9. doi: 10.1158/1078-0432.CCR-07-1508.

PMID:
18316570
[PubMed - indexed for MEDLINE]
Free Article
17.

Phase I/II trial of vinorelbine and divided-dose carboplatin in advanced non-small cell lung cancer.

Masters GA, Hahn EA, Shevrin DH, Kies MS.

Lung Cancer. 2003 Feb;39(2):221-6.

PMID:
12581577
[PubMed - indexed for MEDLINE]
18.

Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response.

Vollmer RT, Govindan R, Graziano SL, Gamble G, Garst J, Kelley MJ, Christenson RH.

Clin Cancer Res. 2003 May;9(5):1728-33.

PMID:
12738727
[PubMed - indexed for MEDLINE]
Free Article
19.

Early response to platinum-based first-line chemotherapy in non-small cell lung cancer may predict survival.

Sirohi B, Ashley S, Norton A, Popat S, Hughes S, Papadopoulos P, Priest K, O'Brien M.

J Thorac Oncol. 2007 Aug;2(8):735-40.

PMID:
17762340
[PubMed - indexed for MEDLINE]
20.

Influence of smoking on histologic type and the efficacy of adjuvant chemotherapy in resected non-small cell lung cancer.

Zhang Z, Xu F, Wang S, Li N, Wang C.

Lung Cancer. 2008 Jun;60(3):434-40. Epub 2007 Nov 26.

PMID:
18036699
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk